Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Enveric Biosciences ( (ENVB) ).
On May 29, 2025, Enveric Biosciences, Inc. held its 2025 Annual Meeting of Stockholders, where 48.81% of the outstanding shares were represented. During the meeting, stockholders voted on four key matters, including the election of six directors, approval of executive compensation, a conditional reverse stock split proposal, and the ratification of CBIZ CPAs P.C. as the independent auditor for 2025. The results of these votes will influence the company’s governance and financial strategies, particularly the conditional reverse stock split, which aims to address potential Nasdaq listing requirements.
The most recent analyst rating on (ENVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.
Spark’s Take on ENVB Stock
According to Spark, TipRanks’ AI Analyst, ENVB is a Underperform.
Enveric Biosciences faces significant financial difficulties, with no revenue and ongoing losses, which heavily impacts its overall score. The technical indicators suggest a bearish trend, adding to the negative outlook. The valuation component is challenging due to negative earnings, making the stock less attractive. Overall, the company’s financial instability is the most significant factor affecting its stock score.
To see Spark’s full report on ENVB stock, click here.
More about Enveric Biosciences
Average Trading Volume: 197,343
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.04M
See more data about ENVB stock on TipRanks’ Stock Analysis page.